[
  {
    "ts": null,
    "headline": "Professional Basketball Player Erica Wheeler and Hologic Team Up to Champion Cervical Cancer Screening",
    "summary": "MARLBOROUGH, Mass., January 13, 2026--Professional Basketball Player Erica Wheeler and Hologic Team Up to Champion Cervical Cancer Screening",
    "url": "https://finnhub.io/api/news?id=9b1e25b31e649ce581dfcf59afca3ea2883acfd338a26b140ba6f3288e765238",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768312800,
      "headline": "Professional Basketball Player Erica Wheeler and Hologic Team Up to Champion Cervical Cancer Screening",
      "id": 138084718,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HOLX",
      "source": "Yahoo",
      "summary": "MARLBOROUGH, Mass., January 13, 2026--Professional Basketball Player Erica Wheeler and Hologic Team Up to Champion Cervical Cancer Screening",
      "url": "https://finnhub.io/api/news?id=9b1e25b31e649ce581dfcf59afca3ea2883acfd338a26b140ba6f3288e765238"
    }
  },
  {
    "ts": null,
    "headline": "How Recent Analyst Moves Are Rewriting The Story For Hologic (NasdaqGS:HOLX)",
    "summary": "The latest update on Hologic centers on a very slight trim to the fair value estimate, from about US$76.50 to about US$76.42 per share. This keeps it closely aligned with the proposed acquisition terms that many Street targets now cluster around. Under the hood, the model has only minor tweaks to the discount rate, revenue growth input and other core assumptions. This lines up with how research firms are treating the deal price as the main reference point rather than reshaping their long term...",
    "url": "https://finnhub.io/api/news?id=b379670e622dd23c4f9f1b0ec899663a495a9edeff18d8a1684e19f08c90a016",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768263446,
      "headline": "How Recent Analyst Moves Are Rewriting The Story For Hologic (NasdaqGS:HOLX)",
      "id": 138083327,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "HOLX",
      "source": "Yahoo",
      "summary": "The latest update on Hologic centers on a very slight trim to the fair value estimate, from about US$76.50 to about US$76.42 per share. This keeps it closely aligned with the proposed acquisition terms that many Street targets now cluster around. Under the hood, the model has only minor tweaks to the discount rate, revenue growth input and other core assumptions. This lines up with how research firms are treating the deal price as the main reference point rather than reshaping their long term...",
      "url": "https://finnhub.io/api/news?id=b379670e622dd23c4f9f1b0ec899663a495a9edeff18d8a1684e19f08c90a016"
    }
  }
]